|[January 11, 2013]
Research and Markets: FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/hct3j6/flublok_seasonal)
has announced the addition of GlobalData's new report "FluBlok (Seasonal
Influenza Vaccines) Forecast and Market Analysis" to their offering.
FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection.
Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and
Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin
garner the majority stake of th market. However, with the entrance of
vaccines with novel routes of administration, such as AstraZeneca's
intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects
a dramatic shift favoring the adoption of such vaccines over the
traditional intramuscular vaccines. GlobalData also anticipates that
manufacturers that launch quadrivalent formulations will steal market
share, patient share, and revenue from the trivalent influenza vaccines
FluBlok is being developed by the Protein Sciences Corporation (PSC),
headquartered in Meriden, Connecticut in the US. FluBlok is the leading
vaccine candidate in PSC's vaccine portfolio that also focuses on
pandemic influenza, SARS and flu vaccine adjuvants. The trivalent
vaccine consists of recombinant hemagglutinin protein, from H1, H3 and B
strains, that are propagated in a baculovirus expression vector system
in insect cells (FDA Briefing document). The vaccine is a first-in-class
product that is the first vaccine to use an insect cell-based
manufacturing system in the US.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/hct3j6/flublok_seasonal
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]